Thymosin β4 regulates migration of colon cancer cells by a pathway involving interaction with Ku80

Annals of the New York Academy of Sciences

Volumn 1194, Issue , 2010, Pages 60-71

  Cierniewski, Czeslaw S ^a,b   Papiewska Pajak, Izabela ^b   Malinowski, Mariusz ^a   Sacewicz Hofman, Izabela ^b   Wiktorska, Magdalena ^b   Kryczka, Jakub ^a   Wysocki, Tomasz ^a   Niewiarowska, Jolanta ^a   Bednarek, Radoslaw ^a  

^a INSTITUTE OF MEDICAL BIOLOGY   (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Colorectal carcinoma cells; Invasiveness; Matrix metalloproteinases; Thymosin 4

Indexed keywords

CELL PROTEIN; D DIMER; FIBRIN; GELATINASE A; GELATINASE B; MATRILYSIN; MONOCLONAL ANTIBODY; PROTEIN KU80; SMALL INTERFERING RNA; THYMOSIN BETA4; UNCLASSIFIED DRUG; VASCULOTROPIN A; INTEGRIN; MATRIX METALLOPROTEINASE; THYMOSIN; THYMOSIN BETA(4);

ACETYLATOR PHENOTYPE; CANCER CELL; CANCER STAGING; CELL MIGRATION; CELL STRAIN HT29; COLON CARCINOGENESIS; COLORECTAL CANCER; CONFERENCE PAPER; CONTROLLED STUDY; FIBRINOLYSIS; HUMAN; HUMAN CELL; PROTEIN INTERACTION; CELL; CELL MOTION; COLON TUMOR; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; GENETICS; METABOLISM; NEOPLASM; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

CELL MOVEMENT; CELLS; COLONIC NEOPLASMS; ENDOTHELIAL CELLS; EXTRACELLULAR MATRIX; HUMANS; INTEGRINS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; NEOPLASMS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; THYMOSIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77951821059     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05480.x     Document Type: Conference Paper

References (78)

1. Fearon, E.R. & B. Vogelstein. 1990. A genetic model for colorectal tumorigenesis. Cell 61: 759-767.
2. Vernon, A.E. & C. Labonne. 2004. Tumor metastasis: A new twist on epithelial-mesenchymal transitions. Curr. Biol. 14: 719-721.
3. Nathke, I.S. 2004. The adenomatous polyposis coli protein: The Achilles heel of the gut epithelium. Annu. Rev. Cell Dev. Biol. 20: 337-366.
4. Kikuchi, A. 2000. Regulation of beta-catenin signaling in theWnt pathway. Biochem. Biophys. Res. Commun. 268: 243-248. (Pubitemid 30119606)
5. Hamada, F.& M. Bienz. 2002.ADrosophilaAPCtumour suppressor homologue functions in cellular adhesion. Nat. Cell Biol. 4: 208-213.
6. Etienne-Manneville, S. & A. Hall. 2003. Cdc42 regulates GSK-3beta and adenomatous polyposis coli to control cell polarity. Nature 421: 753-756.
7. Sansom, O.J., K.R. Reed, A.J. Hayes, et al. 2004. Loss of Apc in vivo immediately perturbs Wnt signaling, differentiation, and migration. Genes Dev. 18: 1385-1390.
8. Mulcahy, H.E. & M.J. Farthing. 1997. K-ras mutations are found in DNA extracted from the plasma of patients with colorectal cancer.Gastroenterology 112: 1114-1120.
9. Guan, R.J., Y. Fu, P.R. Holt & A.B. Pardee. 1999. Association of K-ras mutations with p16 methylation in human colon cancer. Gastroenterology 116: 1063-1071.
10. Li, J., Y. Mizukami, X. Zhang, et al. 2005. Oncogenic K-ras stimulates Wnt signaling in colon cancer through inhibition of GSK-3beta. Gastroenterology 128: 1907-1918.
11. Liu, B., N.C. Nicolaides, S. Markowitz, et al. 1995. Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability. Nat. Genet. 9: 948-955.
12. Popat, S., R. Hubner & R.S. Houlston. 2005. Systematic review of microsatellite instability and colorectal cancer prognosis. J. Clin. Oncol. 23: 609-618.
13. Clark, E.A., T.R. Golub, E.S. Lander & R.O. Hyens. 2000. Genomic analysis of metastasis reveals an essential role for RhoC. Nature 406: 532-535.
14. Xie, D., A. Jauch, C.W. Miller, et al. 2002. Discovery of over-expressed genes and genetic alterations in breast cancer cells using a combination of suppression subtractive hybridization, multiplex FISH and comparative genomic hybridization. Int. J. Oncol. 21: 499-507.
15. Kobayashi, T., F. Okada, N. Fuji, et al. 2002. Thymosinbeta4 regulates motility and metastasis of malignant mouse fibrosarcoma cells. Am. J. Pathol. 160: 869-882.
16. Wang,W.S., P.M. Chen, H.L. Hsiao, et al. 2004. Overexpression of the thymosin beta-4 gene is associated with increased invasion of SW480 colon carcinoma cells and the distant metastasis of human colorectal carcinoma. Oncogene 23: 6666-6671.
17. Abrams, S.I. 2005. Positive and negative consequences of Fas/Fas ligand interactions in the antitumor response. Front. Biosci. 10: 809-821.
18. Hsiao, H.L.,W.S.Wang, P.M. Chen & Y. Su. 2006. Overexpression of thymosin β4 renders SW480 colon carcinoma cells more resistant to apoptosis triggered by FasL and two topoisomerase II inhibitors via down-regulating Fas and upregulating Survivin expression, respectively. Carcinogenesis 27: 936-944.
19. Huang,C.M.,H.N.Ananthaswamy, S. Barnes, et al. 2006. Mass spectrometric proteomics profiles of in vivo tumor secretomes: Capillary ultrafiltration sampling of regressive tumor masses. Proteomics 6: 6107-6116.
20. Declan Fleming, R.Y. 1998. Colorectal cancer screening and follow-up. Surg. Oncol. 7: 125-137.
21. Munshi, H.G. & M.S. Stack. 2006. Reciprocal interactions between adhesion receptor signaling and MMP regulation. Cancer Metastasis Rev. 25: 45-56.
22. Horiuchi, S., H. Yamamoto, Y.Min, et al. 2003. Association of ets-related transcriptional factor E1AF expression with tumour progression and overexpression of MMP-1 and matrilysin in human colorectal cancer. J. Pathol. 200: 568-576.
23. Fridman,R., M.Toth, I.Chvyrokova, et al. 2003.Cell surface association of matrix metalloproteinase-9 (gelatinase B). Cancer Metastasis Rev. 22: 153-166. (Pubitemid 36561055)
24. Galvez,B.G., S.Matias-Roman,M.Yanez-Mo, et al. 2002. ECM regulatesMT1-MMP localization with beta1 or alphavbeta3 integrins at distinct cell compartments modulating its internalization and activity on human endothelial cells. J. Cell Biol. 159: 509-521.
25. Zucker, S. & J. Vacirca. 2004. Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev. 23: 101-117.
26. Al-Nedawi, K.N.,M. Czyz, R. Bednarek, et al. 2004. Thymosin β4 induces the synthesis of plasminogen activator inhibitor-1 in cultured endothelial cells and increases its extracellular expression. Blood 103: 1319-1324.
27. Stamenkovic, I. 2003. Extracellular matrix remodelling: The role of matrixmetalloproteinases. J. Pathol. 200: 448-464.
28. Toth, M., D.C. Gervasi & R. Fridman. 1997. Phorbol ester-induced cell surface association of matrix metalloproteinase-9 in human MCF10A breast epithelial cells. Cancer Res. 57: 3159-3167.
29. Yu,Q.& I. Stamenkovic. 2000.Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGFbeta and promotes tumor invasion and angiogenesis. Genes Dev. 14: 163-176.
30. Brooks, P.C., S. Strömblad, L.C. Sanders, et al. 1996. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interactionwith integrin alpha v beta 3. Cell 85: 683-693.
31. Fridman, R., T.R. Fuerst, R.E. Bird, et al. 1992. Domain structure of human 72-kDa gelatinase/type IV collagenase. Characterization of proteolytic activity and identification of the tissue inhibitor of metalloproteinase-2 (TIMP-2) binding regions. J. Biol. Chem. 267: 15398-15405.
32. Deryugina,E.I.,M.A. Bourdon, K. Jungwirth, et al. 2000. Functional activation of integrin alpha V beta 3 in tumor cells expressing membrane-type 1 matrix metalloproteinase. Int. J. Cancer 86: 15-23.
33. Silletti, S., T.Kessler, J. Goldberg, et al. 2001. Disruption of matrix metalloproteinase 2 binding to integrin alpha vbeta 3 by an organic molecule inhibits angiogenesis and tumor growth in vivo. Proc. Natl. Acad. Sci. USA. 98: 119-124.
34. Stefanidakis, M., M. Bjo, E. Ihanus, et al. 2003. Identification of a negatively charged peptide motif within the catalytic domain of progelatinases that mediates binding to leukocyte beta 2 integrins. J. Biol. Chem. 278: 34674-34684.
35. Redondo-Munoz, J., E. Escobar-Diaz, R. Samaniego, et al. 2006. MMP-9 in B-cell chronic lymphocytic leukemia is up-regulated by alpha4beta1 integrin or CXCR4 engagement via distinct signaling pathways, localizes to podosomes, and is involved in cell invasion and migration. Blood 108: 3143-3151.
36. Morgan, M.R., G.J. Thomas, A. Russell, et al. 2004. The integrin cytoplasmic-tail motif EKQKVDLSTDCis sufficient to promote tumor cell invasionmediated by matrix metalloproteinase (MMP)-2 or MMP-9. J. Biol. Chem. 279: 26533-26539.
37. Coussens, L.M., B. Fingleton & L.M. Matrisian. 2002. Matrix metalloproteinase inhibitors and cancer: Trials and tribulations. Science 295: 2387-2392.
38. Davis, T.L., I. Rabinovitz, B.W. Futscher, et al. 2001. Identification of a novel structural variant of the alpha 6 integrin. J. Biol. Chem. 276: 26099-26106.
39. Monferran, S., J. Paupert, S. Dauvillier, et al. 2004. The membrane form of the DNA repair protein Ku interacts at the cell surface withmetalloproteinase 9. EMBO J. 23: 3758-3768. (Pubitemid 39389707)
40. Bakalkin, G., T. Yakovleva, Y.L. Hurd, et al. 1998. Autoantigen Ku in the brain. Developmentally regulated expression and subcellular localization. Neuroreport 9: 2147-2151.
41. Prabhakar, B.S., G.P. Allaway, J. Srinivasappa & A.L. Notkins. 1990.Cell surface expression of the 70-kD component of Ku, a DNA-binding nuclear autoantigen. J. Clin. Invest. 86: 1301-1305.
42. Dalziel, R.G., S.C. Mendelson & J.P. Quinn. 1992. The nuclear autoimmune antigen Ku is also present on the cell surface. Autoimmunity 13: 265-267.
43. Ginis, I. & D.V. Faller. 2000. Hypoxia affects tumor cell invasiveness in vitro: The role of hypoxia-activated ligand HAL1/13 (Ku86 autoantigen). Cancer Lett. 154: 163-174.
44. Lynch, E.M., R.B. Moreland, I. Ginis, et al. 2001. Hypoxia-activated ligand HAL-1/13 is lupus autoantigen Ku80 and mediates lymphoid cell adhesion in vitro. Am. J. Physiol. Cell Physiol. 280: C897-C911.
45. Lucero, H., D. Gae & G.E. Taccioli. 2003. Novel localization of the DNAPK complex in lipid rafts: A putative role in the signal transduction pathway of the ionizing radiation response. J. Biol. Chem. 278: 22136-22143.
46. Teoh, G., M. Urashima, E.A. Greenfield, et al. 1998. The 86-kD subunit of Ku autoantigen mediates homotypic and heterotypic adhesion of multiple myeloma cells. J. Clin. Invest. 101: 1379-1388.
47. Jackson, S.P. 2002. Sensing and repairing DNA doublestrand breaks. Carcinogenesis 23: 687-696.
48. Sawada,M., P.Hayes & S.Matsuyama. 2003.Cytoprotective membrane-permeable peptides designed from the Bax-binding domain of Ku70. Nat. Cell Biol. 5: 352-357.
49. Huo, N., Y. Ichikawa, M. Kamiyama, et al. 2002. MMP-7 (matrilysin) accelerated growth of human umbilical vein endothelial cells. Cancer Lett. 177: 95-100.
50. Adachi, Y., F. Itoh, H. Yamamoto, et al. 2001. Retinoic acids reduce matrilysin (matrixmetalloproteinase 7) and inhibit tumor cell invasion in human colon cancer. Tumour Biol. 22: 247-253.
51. Zeng, Z.S.,W.P. Shu, A.M. Cohen & J.G. Guillem. 2002. Matrix metalloproteinase-7 expression in colorectal cancer liver metastases: Evidence for involvement ofMMP-7 activation in human cancer metastases. Clin. Cancer Res. 8: 144-148.
52. Kioi,M., K. Yamamoto, S.Higashi, et al. 2003.Matrilysin (MMP-7) induces homotypic adhesion of human colon cancer cells and enhances their metastatic potential in nude mouse model. Oncogene 22: 8662-8670.
53. Mimori, K., K. Yamashita, M. Ohta, et al. 2004. Coexpression of matrix metalloproteinase-7 (MMP-7) and epidermal growth factor (EGF) receptor in colorectal cancer: An EGFreceptor tyrosine kinase inhibitor is effective againstMMP-7-expressing cancer cells. Clin. Cancer Res. 10: 8243-8249.
54. Strand, S., P. Vollmer, L. Van Den Abeelen, et al. 2004. Cleavage ofCD95by matrixmetalloproteinase-7 induces apoptosis resistance in tumour cells. Oncogene 23: 3732-3736.
55. Knudsen, H., T.Olesen, A. Riccio, et al. 1994. A common response elementmediates differential effects of phorbol esters and forskolin on type-1 plasminogen activator inhibitor gene expression in human breast carcinoma cells. Eur. J. Biochem. 220: 63-74.
56. Muegge, K.,M.Vila, G.L. Gusella, et al. 1993. Interleukin 1 induction of the c-jun promoter. Proc. Natl. Acad. Sci. USA. 90: 7054-7058.
57. Huang, H.C., C.H. Hu, M.C. Tang, et al. 2007. Thymosin β4 triggers an epithelial-mesenchymal transition in colorectal carcinoma by upregulating integrin-linked kinase. Oncogene 26: 2781-2790.
58. Angel, P., A. Szabowski & M. Schorpp-Kistner. 2001. Function and regulation of AP-1 subunits in skin physiology and pathology. Oncogene 20: 2413-2423.
59. Benbow,U.& C.E. Brinckerhoff. 1997. The AP-1 site and MMP gene regulation: What is all the fuss about? Matrix Biol. 15: 519-526.
60. Eberhardt,W.,A.Huwiler,K.F. Beck, et al. 2000.Amplification of IL-1 beta-induced matrix metalloproteinase-9 expression by superoxide in rat glomerular mesangial cells is mediated by increased activities of NF-kappa B and activating protein-1 and involves activation of the mitogen-activated protein kinase pathways. J. Immunol. 165: 5788-5797.
61. Zeigler, M.E., Y. Chi, T. Schmidt & J. Varani. 1999. Role of ERK and JNK pathways in regulating cell motility and matrixmetalloproteinase 9 production in growth factorstimulated human epidermal keratinocytes. J. Cell. Physiol. 180: 271-284.
62. Lin, C.C., C.T. Kuo, C.Y. Cheng, et al. 2009. L-1 beta promotes A549 cell migration via MAPKs/AP-1- and NF-kappaB-dependent matrix metalloproteinase-9 expression. Cell. Signaling 21: 1652-1662.
63. Bednarek,R., J. Boncela, K. Smolarczyk, et al. 2008.KU80 as a novel receptor for thymosin β4 that mediates its intracellular activity different from G actin sequesterin. J. Biol. Chem. 283: 1534-1544.
64. Mimori, T., Y. Ohosone, N. Hama, et al. 1990. Isolation and characterization of cDNA encoding the 80- kDa subunit protein of the human autoantigen Ku (p70/p80) recognized by autoantibodies from patients with scleroderma-polymyositis overlap syndrome. Proc. Natl. Acad. Sci. USA 87: 1777-1781.
65. Walker, J.R., R.A. Corpina & J. Goldberg. 2001. Structure of the Ku heterodimer bound to DNA and its implications for double-strand break repair. Nature 412: 607-614.
66. Myung, K., G. Ghosh, F.J. Fattah, et al. 2004. Regulation of telomere length and suppression of genomic instability in human somatic cells by Ku86. Mol. Cell. Biol. 24: 5050-5059.
67. Gullo, C., M. Au, G. Fang & G. Teoh. 2006. The biology of Ku and its potential oncogenic role in cancer. Biochim. Biophys. Acta 1765: 223-234.
68. Muller, C., J. Paupert, S. Monferran & B. Salles. 2005. The double life of the Ku protein: Facing the DNA breaks and the extracellular environment. Cell Cycle 4: 438-441.
69. Monferran, S., J. Paupert, S. Dauvillier, et al. 2004. The membrane form of the DNA repair protein Ku interacts at the cell surface with metalloproteinase 9. EMBO J. 23: 3758-3768. (Pubitemid 39389707)
70. Adam, L., D. Bandyopadhyay & R. Kumar, 2000. Interferon-alpha signaling promotes nucleus-tocytoplasmic redistribution of p95Vav, and formation of a multisubunit complex involving Vav, Ku80, and Tyk2. Biochem. Biophys. Res. Commun. 267: 692-696.
71. Lynch, E.M., R.B. Moreland, I. Ginis, et al. 2001. Hypoxia-activated ligand HAL-1/13 is lupus autoantigen Ku80 and mediates lymphoid cell adhesion in vitro. Am. J. Physiol. 280: C897-C911.
72. Morio, T., S.H. Hanissian, L.B. Bacharier, et al. 1999. Ku in the cytoplasm associates with CD40 in human B cells and translocates into the nucleus following incubation with IL-4 and anti-CD40 mAb. Immunity 11: 339-348.
73. Giffin,W.,H.Torrance,D.J.Rodda, et al. 1996. Sequencespecific DNA binding by Ku autoantigen and its effects on transcription. Nature 380: 265-268.
74. Liu, E.S. & A.S. Lee. 1991. Common sets of nuclear factors binding to the conserved promoter sequence motif of two coordinately regulated ER protein genes, GRP78 and GRP94. Nuleic Acids Res. 19: 5425-5431.
75. Grote, J., S.Koenig,D.Ackermann, et al. 2006. Identification of poly(ADP-ribose)polymerase-1 and Ku70/Ku80 as transcriptional regulators of S100A9 gene expression. BMC Mol. Biol. 48: 1-10.
76. Brieger, A., G. Plotz, S. Zeuzem & J. Trojan. 2007. Thymosin beta 4 expression and nuclear transport are regulated by hMLH1. Biochem. Biophys. Res. Commun. 364: 731-736.
77. Wu, X., J.L. Platt & M. Cascalho. 2003. Dimerization of MLH1 and PMS2 limits nuclear localization of MutLalpha. Mol. Cell. Biol. 23: 3320-3328.
78. Clark, A.J., R. Barnetson, S.M. Farrington & M.G. Dunlop. 2004. Prognosis in DNA mismatch repair deficient colorectal cancer: Are all MSI tumours equivalent? Fam. Cancer 3: 85-91.